Switching from abciximab to eptifibatide for percutaneous coronary interventions: A local analysis (SWAP study)

Canadian Journal of Cardiology

Volumn 19, Issue 7, 2003, Pages 809-814

  Leung, Vivian W Y ^a   Sunderji, Rubina ^a,b   Zed, Peter J ^a,b   Gin, Ken ^b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Angina; Angioplasty; Myocardial infarction; Platelet aggregation inhibitors

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANGIOTENSIN II ANTAGONIST; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; LONG ACTING DRUG; NITRATE; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE; UNCLASSIFIED DRUG; WARFARIN; ANTITHROMBOCYTIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PEPTIDE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLEEDING; COMPARATIVE STUDY; CONTROLLED STUDY; DEATH; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; ST SEGMENT ELEVATION; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION; TREATMENT OUTCOME; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METHODOLOGY; MIDDLE AGED; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; SYNDROME; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PEPTIDES; PHYSICIAN'S PRACTICE PATTERNS; PLATELET AGGREGATION INHIBITORS; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES; SYNDROME; TREATMENT OUTCOME;

EID: 0042131577     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. The EPIC Investigator. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 1994;330:956-61.
2. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-35.
3. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
4. The EPISTENT Investigators. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial. Lancet 1999;354:2019-24.
5. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903.
6. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-8.
7. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Lancet 2000;356:2037-44.
8. Kong DF, Califf RM, Miller DP, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998;98:2829-35.
9. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Unstable Angina). Circulation 2000;102:1193-209.
10. Smith SC Jr., Dove JT, Jacobs AK, et al. ACC/AHA guidelines for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 2001;37:2239I-1XVI.
11. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined - A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.
12. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
13. Sheehan FH, Braunwald E, Canner P, et al. The effect of intravenous thrombolytic therapy on left ventricular function: A report on tissue-type plasminogen activator and streptokinase from the Thrombolysis In Myocardial Infarction (TIMI Phase I) trial. Circulation 1987;75:817-29.
14. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL for the TIMI Investigators. Thrombolysis in Myocardial Infarction (TIMI) Trial - Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
15. Dasgupta H, Blankenship JC, Wood GC, Frey CM, Demko SL, Menapace FJ. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: A pooled analysis. Am Heart J 2000;140:206-11.
16. Reopro. In: Repchinsky C. Compendium of Pharmaceuticals and Specialties. Ontario: Canadian Pharmacists Association, 2002:1453-5.
17. Integrilin. In: Repchinsky C. Compendium of Pharmaceuticals and Specialties. Ottawa: Canadian Pharmacists Association, 2002:807-10.
18. Tcheng, JE. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment. Am J Cardiol 1999;83(Suppl 1):7-11.
19. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revasculaarization. N Engl J Med 2001;344:1888-94.
20. Dobesh PP, Abu-Shanab JR, Schroeder SL, Lakamp JE. Outcomes associated with a change in selection of glycoprotein IIb/IIIa agents in a community hospital setting. Pharmacotherapy 2000;20:1234-5. (Abst)
21. Lam W, Gill JB, Trask RV, et al. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro Versus Integrilin Cost Evaluation (PRICE) Trial. Am Heart J 2001;141:402-9.
22. Nikhil JY, Radhakrishnan S, Paradiso-Hardy FL, Cohen EA. Clopidogrel in interventional cardiology: Questions answered and questions remaining. Can J Cardiol 2002;18:739-48.
23. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358:527-33.
24. Gurbel PA, Malinin Al, Callahan KP, Serebruany VL, O'Connor CM. Effect of loading with clopidogrel at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. Am J Cardiol 2002;90:312-5.
25. Blankenship JC. Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors. Am Heart J 1999;138:S287-96.
26. Rebeiz AG, Pieper KS, O'Shea JC, et al. 16 to 18-hour infusions of eptifibatide seem optimal in reducing ischemic complications following percutaneous coronary intervention. Circulation 2001;104(Suppl II):II-386. (Abst)
27. Lage MJ, Barber BL, McCollam PL, Bala M, Scherer J. Impact of abciximab versus eptifibatide on length of hospital stay for PCI patients. Cathet Cardiovasc Intervent 2001;53:296-303.